Natural killer cells and tumor control

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 514-521

  Cooley, Sarah ^a   Weisdorf, Daniel S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

adoptive immunotherapy; hematopoietic cell transplantation; killer immunoglobulin like receptors; natural killer cells

Indexed keywords

CHEMOKINE; CYTOKINE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CELL FUNCTION; CYTOKINE PRODUCTION; DONOR SELECTION; GENE; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; INFECTION CONTROL; KIR GENE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PRIORITY JOURNAL; REVIEW; TARGET CELL;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS;

EID: 78049308471     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833f10f1     Document Type: Review

References (112)

1. Herberman RB, Ortaldo JR. Natural killer cells: their roles in defenses against disease. Science 1981; 214:24-30.
2. Kiessling R, Petranyi G, Klein G, Wigzel H. Genetic variation of in vitro cytolytic activity and in vivo rejection potential of nonimmunized semi-syn-geneic mice against a mouse lymphoma line. Int J Cancer 1975; 15:933-940.
3. Miller JS, McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 2001; 98:705-713.
4. Yu H, FehnigerTA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood 1998; 92:3647-3657.
5. Muench MO, Humeau L, Paek B, et al. Differential effects of interleukin-3, interleukin-7, interleukin 15, and granulocyte-macrophage colony-stimulating factor in the generation of natural killer and B cells from primitive human fetal liver progenitors. Exp Hematol 2000; 28:961-973.
6. Freud AG, Yokohama A, Becknell B, et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006; 203:1033-1043.
7. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97:3146-3151.
8. Chan A, Hong DL, Atzberger A, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007; 179:89-94.
9. Singh SM, Yanagawa H, Hanibuchi M, et al. Augmentation by interleukin-18 of MHC-nonrestricted killer activity of human peripheral blood mononuclear cells in response to interleukin-12. Int J Immunopharmacol 2000; 22:35-43.
10. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005; 86:209-239.
11. Huntington ND, Legrand N, Alves NL, et al. IL-15 trans-presentation pro-motes human NK cell development and differentiation in vivo. J Exp Med 2009; 206:25-34.
12. Moretta L, Ferlazzo G, Bottino C, et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006; 214:219-228.
13. WalzerT, Dalod M, Robbins SH, et al. Natural-killer cells and dendritic cells: 'l'union fait la force'. Blood 2005; 106:2252-2258.
14. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010; 115:2167-2176.
15. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20:323-370.
16. Mace EM, Zhang J,Siminovitch KA,Takei F. Elucidation of the integrin LFA-1-mediated signaling pathway of actin polarization in natural killer cells. Blood 2010.
17. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457:557-561.
18. Yokoyama WM, Daniels BF, Seaman WE, et al. A family of murine NK cell receptors specific for target cell MHC class I molecules. Semin Immunol 1995; 7:89-101.
19. Vales-Gomez M, Reyburn HT, Mandelboim M, Strominger JL. Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors. Immunity 1998; 9:337-344.
20. Moesta AK, Norman PJ, Yawata M, et al. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008; 180:3969-3979.
21. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991; 173:1017-1020.
22. Lopez-Botet M, Angulo A, Guma M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens 2004; 63:195-203.
23. Moretta L, Bottino C, Pende D, et al. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18:151-158.
24. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 2008; 83:799-803.
25. CudkowiczG, Bennett M. Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice. J Exp Med 1971; 134:83-102.
26. CudkowiczG, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 1971; 134:151 3-1528.
27. Murphy WJ, Kumar V, Bennett M. Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med 1987; 166:1499-1509.
28. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319:675-678.
29. Ljunggren HG, Karre K. In search of the 'missing self: MHC molecules and NK cell recognition. Immunol Today 1990; 11:237-244.
30. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436:709-713.
31. Yokoyama WM, Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006; 214:143-154.
32. Raulet DH. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol 2006; 18:145-150.
33. Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev 2006; 214:130-142.
34. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev 2006; 214:155-160.
35. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001; 19:291-330.
36. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997; 7:739-751.
37. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-342.
38. Cooley S,Xiao F, Pitt M, et al. Asubpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 2007; 110:578-586.
39. Joncker NT, Fernandez NC, Treiner E, et al. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol 2009; 182:4572-4580.
40. Brodin P, Karre K, Hoglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009; 30:143-149.
41. Foley BA, De Santis D, Van Beelen E, et al. The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 2008; 112:435-443.
42. Fauriat C, Ivarsson MA, Ljunggren HG, et al. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010; 115:1166-1174.
43. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005; 26:221-226.
44. Soriani A, Zingoni A, Cerboni C, et al. ATM-ATR dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113:3503-3511.
45. Stein MN, Shin J, Gudzowaty O, et al. Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. Anticancer Res 2006; 26 (3A):1759-1763.
46. Pende D, Spaggiari GM, Marcenaro S, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105:2066-2073.
47. Re F, Staudacher C, Zamai L, et al. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer 2006; 107:640-648.
48. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65:6321-6329.
49. Feuchtinger T, Pfeiffer M, Pfaffle A, et al. Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone Marrow Transplant 2009; 43:875-881.
50. Godal R, Bachanova V, Gleason M, et al. NK cell killing of AML and ALL blasts by killer-immunoglobulin receptor (KIR) negative NKcells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant 2010; 16:612-621.
51. Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28:571-580.
52. Brenner CD, King S, Przewoznik M, et al. Requirements for control of B-cell lymphoma by NK cells. Eur J Immunol 2010; 40:494-504.
53. Langenkamp U, Siegler U, Jorger S, et al. Human acute myeloid leukemia CD34+CD38-stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells. Haematologica 2009; 94:1590-1594.
54. Carlsten M, Baumann BC, Simonsson M, et al. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34(+) blasts in myelodysplastic syndrome. Leukemia 2010. [Epub ahead of print]
55. Baessler T, Charton JE, Schmiedel BJ, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010; 115:3058-3069.
56. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285:412-415.
57. Lundqvist A, McCoy JP, Samsel L,Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007; 109:3603-3606.
58. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100.
59. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110:433-440.
60. Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004; 63:204-211.
61. Lowe EJ, Turner V, Handgretinger R, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-nonidentical paediatric bone marrow transplantation. Br J Haematol 2003; 123:323-326.
62. Nguyen S, Dhedin N, Vernant JP, et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005; 105:4135-4142.
63. DaviesSM, Ruggieri L, DeForT, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglo-bulin-like receptor. Blood 2002; 100:3825-3827.
64. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102:814-819.
65. Beelen DW, Ottinger HD, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105:2594-2600.
66. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12:876-884.
67. Hsu KC, GooleyT, Malkki M, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12:828-836.
68. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109:5058-5061.
69. Brunstein CG, Wagner JE, Weisdorf DJ, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009; 113:5628-5634.
70. Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23:492-500.
71. Venstrom JM, Zheng J, Noor N, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009; 15:7330-7334.
72. Shilling HG, McQueen KL, Cheng NW, et al. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101:3730-3740.
73. Cooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106:4370-4376.
74. Clausen J, Kircher B, Auberger J, et al. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. Biol Blood Marrow Transplant 2010; 16:273-280.
75. Linn YC, Phang CY, Lim TJ, et al. Effect of missing killer- immunoglobulin-like receptor ligand in recipients undergoing HLA full matched, non-T-depleted sibling donor transplantation: a single institution experience of 151 Asian patients. Bone Marrow Transplant 2010; 45:1031-1037.
76. Gagne K, Busson M, Bignon JD, et al. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1366-1375.
77. Triplett BM, HorwitzEM, Iyengar R, et al. Effects of activating NKcell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia 2009; 23:1278-1287.
78. Baron F, Petersdorf EW, Gooley T, et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Trans plant 2009; 15:580-588.
79. Yu J, Venstrom JM, Liu XR, et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for nonself HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009; 113:3875-3884.
80. Bjorklund AT, Schaffer M, Fauriat C, et al. NK cells expressing inhibitory KIR for nonself-ligands remain tolerant in HLA-matched sibling stem cell trans plantation. Blood 2010; 115:2686-2694.
81. Rathmann S, Glatzel S, Schonberg K, et al. Expansion of NKG2A-LIR1-natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/ HLA-ligand mismatched patients following hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16:469-481.
82. Pende D, MarcenaroS, Falco M, et al. Antileukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113:311 9-3129.
83. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113:726-732.
84. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated trans plantation for acute myelogenous leukemia. Blood 2010. [Epub ahead of print]
85. Giebel S, NowakI, DziaczkowskaJ, et al. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2009; 83:343-356.
86. Venstrom JM, Gooley TA, Spellman S, et al. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hemato poietic stem cell transplantation. Blood 2010; 115:3162-3165.
87. Stringaris K, Adams S, Uribe M, et al. Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukaemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukaemia but not other haematological malignancies. Biol Blood Marrow Transplant 2010.
88. Chen C, Busson M, Rocha V, et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006; 38:437-444.
89. Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010; 16:533-542.
90. Sun JC, Lanier LL Cutting edge: viral infection breaks NK cell tolerance to 'missing self. J Immunol 2008; 181:7453-7457.
91. Orr MT, Murphy WJ, Lanier LL. 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol 2010; 11:321-327.
92. Cook M, Briggs D, Craddock C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006; 107:1230-1232.
93. Tomblyn M, Young JA, Haagenson MD, et al. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant 2010; 16:1155-1161.
94. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-3057.
95. Cooley S, Gada P, McKenna D, et al. Successful haploidentical hematopoietic cell engraftment using a non-myeloablative preparative regimen including natural killer (NK) cells. American Society of Hematology 50th Annual Meeting; San Francisco, CA: Blood; 2008. p. 827.
96. Pfeiffer MM, Feuchtinger T, Teltschik HM, et al. Reconstitution of NK cell receptors influences NK activity and relapse rate after haploidentical transplantation of T and B cell depleted grafts in children. Haematologica 2010; 95:1381-1388.
97. Shi J, Tricot G, Szmania S, et al. Infusion of haplo-identical killer immunoglo-bulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143:641-653.
98. Passweg JR, Tichelli A, Meyer-Monard S, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18:1835-1838.
99. Koehl U, Esser R, Zimmermann S, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr 2005; 217:345-350.
100. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplanta tion in childhood acute myeloid leukemia. J Clin Oncol 2010; 28:955-959.
101. Lugli E, Goldman CK, Perera LP, et al. Transient and persistent effects of IL15 on lymphocyte homeostasis in nonhuman primates. Blood 2010. [Epub ahead of print]
102. Barao I, Hanash AM, Hallett W, et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006; 103:5460-5465.
103. Berg M, Lundqvist A, McCoy P, et al. Clinical-grade exvivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009 11 341-355.
104. Suck G, Branch DR, Smyth MJ, et al. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol 2005; 33:1160-1171.
105. Suck G, Branch DR, Keating A. Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol 2006; 82:355-361.
106. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol 2001; 29:1157-1168.
107. Fujisaki H, Kakuda H,Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69:4010-4017.
108. Vahlne G, Lindholm K, Meier A, et al. In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2. Eur J Immunol 2010; 40:813-823.
109. Romagne F, Andre P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114:2667-2677.
110. Diermayr S, Himmelreich H, Durovic B, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111:1428-1436.
111. Yong AS, Keyvanfar K, Hensel N, et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 2009; 113:875-882.
112. Markel G, Seidman R, Besser MJ, et al. Natural killer lysis receptor (NKLR)/ NKLR-ligand matching as a novel approach for enhancing antitumor activity of allogeneic NK cells. PLoS One 2009; 4:e5597.